Focused On-demand Library for Glucose-dependent insulinotropic receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8TDV5

UPID:

GP119_HUMAN

Alternative names:

G-protein coupled receptor 119

Alternative UPACC:

Q8TDV5; Q495H7; Q4VBN3

Background:

The Glucose-dependent insulinotropic receptor, also known as G-protein coupled receptor 119, plays a pivotal role in metabolic regulation. It serves as a receptor for oleoylethanolamide and lysophosphatidylcholine, substances involved in energy homeostasis and glucose metabolism. Activation of this receptor by its ligands triggers a cascade of events through G proteins, predominantly via a G(s) mediated pathway, leading to the stimulation of adenylate cyclase.

Therapeutic significance:

Understanding the role of the Glucose-dependent insulinotropic receptor could open doors to potential therapeutic strategies. Its involvement in glucose-dependent insulin release positions it as a promising target for the development of treatments for metabolic disorders, including diabetes.